Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT05911308 2025-03-21

Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Phase 1 Terminated

1 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05431270 2025-01-31

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Phase 1/2 Recruiting

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06747169 2024-12-27

Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical Study

Phase 2 Not yet recruiting

32 enrolled

Thoracic

Squamous Non-Small Cell Lung Cancer SqNSCLC

NCT06467617 2024-12-16

Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC

Phase 2 Recruiting

35 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04956692 2024-12-03

MK-3475-A86

Phase 3 Active not recruiting

531 enrolled 18 charts

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03678883 2024-11-07

9-ING-41 in Patients with Advanced Cancers

Phase 2 Active not recruiting

350 enrolled

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT05501665 2024-10-17

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Phase 1/2 Recruiting

25 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02775435 2024-10-08

KEYNOTE-407

Phase 3 Completed

559 enrolled 18 charts 1 FDA

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02250326 2024-09-19

abound2L+

Phase 2 Completed

240 enrolled 23 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT06475755 2024-06-26

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

Phase 2 Not yet recruiting

178 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Phase 3 Terminated

8 enrolled 7 charts

Thoracic

NSCLC

NCT05358548 2024-04-10

ATATcH Alternating Treatment Plans for Advanced Cancer

Phase 2 Recruiting

150 enrolled

Head & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms

NCT05377658 2024-02-21

AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

Phase 2 Recruiting

43 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02716038 2023-12-12

Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC

Phase 2 Completed

39 enrolled 8 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06028633 2023-09-13

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Phase 2 Not yet recruiting

28 enrolled

Thoracic

Advanced Non-squamous Non-small-cell Lung Cancer

NCT02710396 2023-07-24

Genetic Predictors of Benefit to Pembrolizumab

Phase 2 Terminated

19 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03345810 2023-06-15

DURATION

Phase 2 Completed

200 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02382406 2023-05-23

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

Phase 1/2 Terminated

46 enrolled 24 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

Phase 1 Terminated

159 enrolled

DermatologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT03138889 2023-03-10

PROPEL

Phase 1/2 Terminated

162 enrolled 21 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04338620 2023-03-06

Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC

Phase 2 Unknown

94 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02039674 2022-11-08

MK-3475-021

Phase 1/2 Completed

267 enrolled 24 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02967133 2022-09-08

A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

Phase 2 Terminated

7 enrolled 9 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00347412 2022-07-25

Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

Phase 3 Completed

903 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Pericardial Effusion

NCT04210037 2022-07-12

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Phase 1/2 Terminated

28 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04459611 2022-07-12

neoSCORE

Phase 2 Unknown

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00533949 2022-06-21

High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 3 Completed

544 enrolled 21 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiation Injuries

NCT02662634 2022-03-18

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02303977 2021-09-29

Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy

Phase 2 Completed

37 enrolled 10 charts

Thoracic

Adenocarcinoma of Lung

NCT01620190 2021-07-16

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

Phase 2 Completed

26 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04304248 2021-05-06

NeoTAP01

Phase 2 Active not recruiting

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04725448 2021-04-06

Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

Phase 2 Unknown

27 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Thoracic Neoplasms

NCT02733250 2021-02-16

URCOH-PMS-001

Phase 1/2 Completed

10 enrolled

Thoracic

Lung Neoplasms

Clinical Trials

MK-3475-01A

POSEIDON

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

ANTELOPE

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

MK-3475-01G

MK-7684A-007

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

MK-3475A-D77

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

MK-3475A-D77

Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical Study

Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC

MK-3475-A86

9-ING-41 in Patients with Advanced Cancers

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

KEYNOTE-407

abound2L+

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

ATATcH Alternating Treatment Plans for Advanced Cancer

AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Genetic Predictors of Benefit to Pembrolizumab

DURATION

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

Safety Study of SEA-CD40 in Cancer Patients

PROPEL

Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC

MK-3475-021

A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

neoSCORE

High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

NeoTAP01

Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

URCOH-PMS-001